Keywords: ucb, profits, up, reports, full-year, pretax, rose
UCB profits up 23% in 2000
Article | 11 April 2001
UCB reports that full-year pretax profits rose 23% to 2.2 billioneuros ($1.99 billion), with pharmaceutical sales increasing 27% to 1.15 billion euros. The drug sector, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
